Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models - Wikidata - awgldk - TriplyDB

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

http://www.wikidata.org/entity/Q34430739

about

Eribulin in Cancer Treatment Advances in sarcoma diagnostics and treatment Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas Efficacy of eribulin in breast cancer: a short report on the emerging new data.Emerging therapies for breast cancer Drug delivery in a tumour cord model: a computational simulation "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.Review on the clinical use of eribulin mesylate for the treatment of breast cancer.Eribulin in advanced liposarcoma and leiomyosarcoma.Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?Newer medical therapies for metastatic soft tissue sarcoma.Eribulin in non-small cell lung cancer: challenges and potential strategies.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Eribulin shows high concentration and long retention in xenograft tumor tissues.Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using SPring-8 synchrotron radiation microangiography Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports.Marine Sponge Natural Products with Anticancer Potential: An Updated Review.Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.Eribulin in advanced breast cancer: safety, efficacy and new perspectives.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Advances in the treatment of soft tissue sarcoma: focus on eribulin.Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.Primary non-Hodgkin lymphoma of the right femur and subsequent metastasis to the left femur: A case report and literature review.Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.EMT, cell plasticity and metastasis.Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil

P2860

Q26799328-A575C6BC-3788-4091-BE53-24D24C9EADD1 Q28069695-CCB784C7-5303-409E-8D8B-98DFDD612F48 Q28074125-630B9C72-5D4D-458D-807C-DE0E616A7A67 Q28076210-FBC0575E-5185-45F5-8FDE-08A2CB77C8B0 Q28078116-5E93F954-8CAE-4991-89A8-D41C8D9E853A Q31167441-7B67D905-F0D3-42F7-B52B-A677744B7034 Q33617949-4C345F45-FA49-46E5-86DC-BF98213E9A5F Q33748082-4832DBB1-4653-4376-8501-E7C4A61DD1BD Q36361371-8943F9D9-FD8C-49D0-8851-A8C810AFB00C Q36614786-AB879AA7-0BA2-4332-9D30-050B2743B575 Q36742259-B014A77D-9C4E-47CD-B040-C08A9F135B18 Q36922483-B6581D34-AD94-43A2-A07E-2F702C71F388 Q36964337-A94E9025-A809-4DB6-9E2B-BE5D8B64CF13 Q37052387-38703F7F-B2CA-4E3E-B4A1-6FD11D9F5147 Q38686619-0D0DBD14-A9A2-4F31-8E2D-4347B0F96DE6 Q38688042-240C2250-9B2A-4B3A-B92C-EF9A2D4137C0 Q38711371-495B0904-7D15-4BE8-B512-4370ADAABCC5 Q38722807-D8CE373B-613A-486F-94BE-61B05758724A Q38769613-63F4E5C1-3B98-485B-B440-71C52BF64847 Q39012067-B40088E1-1128-4FF5-8195-1E971C165BB7 Q39120142-CA9D809E-AB24-4D96-9A42-CC84B12BCE48 Q41105379-B78AEEFA-4C26-4FF2-9018-C4D57099CEAE Q41159925-E83D5DD8-70D7-42B4-9B7C-F9E4DC9DCD59 Q41591243-D0A57A1D-8741-4A02-BB03-0AC5D1385411 Q42465330-4473B25A-5E53-4382-A76F-428D08EE09C7 Q43245354-4603CBA2-FADE-4A6F-A892-FCE9547AE531 Q44178469-43ACDF41-EE13-40C1-9672-A8BC2A4CDB8D Q46592179-A619BD5E-0076-4E9B-A807-AE185C36F203 Q47239615-D2BE2E62-4B98-4267-864A-9875D736ED8A Q47794057-4680D531-A4C1-4B5B-BA88-67745279C6B1 Q48308048-3DA0C671-047C-44F3-AC04-6966674774C0 Q49261685-811BF4BC-A001-4F88-8D53-F91DBC967138 Q51285275-5E318FF1-9DA2-4F4F-85BB-E4C60D5EFD16 Q52655152-FB01F68F-FB32-4E98-85BC-C497B84B886D Q52664052-577446F0-85FD-4440-9DF8-3EC890C145F2 Q53666394-83A95844-3BA0-4732-8FF2-D514CC9470DA Q54978314-AEB9FAFF-B346-418D-9773-BA979AE91BB9 Q55457104-9B436934-83C7-4BB2-BAD7-0E72B59C0778 Q58777726-D3E0DD77-C1AC-473A-A70D-B236E25CB563

P2860

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

http://www.wikidata.org/entity/Q34430739

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@ast

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@en

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@nl

type

label

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@ast

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@en

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@nl

prefLabel

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@ast

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@en

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@nl

P1433

Q34430739-6A51FEC9-3408-4BA5-9637-084CAE5D3D6A

P1476

Q34430739-6979F1AD-8578-4118-BCB2-D6648EBF3017

P2093

Q34430739-03B2A3CF-843C-4769-BB78-1AD5BD242647

Q34430739-063D2218-EA18-4203-9C9F-46A53E04F19F

Q34430739-0E2305ED-1B32-4D46-B5B4-2DB79818E3D9

Q34430739-2516A0EE-BA48-4748-AF76-AFB4D86EA1E8

Q34430739-39FFEEC0-E0E9-4E54-B968-5C14E4A38B4A

Q34430739-42D7AAA5-6306-4F8F-BA75-4F7899100EC7

Q34430739-4948D8CD-225B-4802-8ADA-509CCD0C7781

Q34430739-64E17220-8D2D-4F05-9FFB-65F5358B72FE

Q34430739-7011B283-AB02-4FC3-80C0-DF51AA005F2F

Q34430739-7F5843A0-FFAE-45C2-A1DB-1E567040B1F8

P2860

Q34430739-021DFA18-E351-416B-9917-682FBEB38D03

Q34430739-1B4FB3F5-8EC4-4939-B08A-C41535F3EEED

Q34430739-1FE30472-4893-4BC1-A533-BC9616A18CB1

Q34430739-204A6751-B31F-4748-A2AB-BA2D8267450F

Q34430739-2576DB14-FCA5-4D03-A72C-C9C0C699FB38

Q34430739-2973EF14-9FC0-4D96-8BC4-96E6CAE04093

Q34430739-2F574756-9562-4AD2-9581-94FBDF0BDBB7

Q34430739-3A287AAB-C66E-49D2-94C2-25F255EE681C

Q34430739-3FFC0FA3-453E-4BFB-957B-A85BEA9EE959

Q34430739-41B67417-4E17-47BF-9CAC-F8460CB0DAC5

P304

Q34430739-09681CD7-2E08-43CC-9E13-CEDB905E8F3D

P31

Q34430739-B1B9C91C-AB2F-4DE4-B7BB-3A8B6A39A1A4

P356

Q34430739-3A4D8583-2BD1-44F6-87F8-0BFCFF40060D

P433

Q34430739-B5DFAED7-9134-4D40-9FC6-481C14873780

P478

Q34430739-6E256B37-2402-4FF1-A49A-7B13F293F548

P50

Q34430739-79D57D76-99D7-46C3-BDB2-6B123CE83927

P577

Q34430739-D75D926A-53E2-4667-AD76-3C818675469A

P5875

Q34430739-74997451-FFFA-48D9-A61A-C3B3CCCDBFBF

P698

Q34430739-164F8287-69E9-409D-9009-A05642B10A92

P932

Q34430739-F259B38F-E239-47E5-8EEC-0C4CD3E2A278

P356

P1433

P1476

Eribulin mesylate reduces tumo ...... cal human breast cancer models

@en

P2093

Hideki Watanabe

http://www.w3.org/2001/XMLSchema#string

Junji Matsui

http://www.w3.org/2001/XMLSchema#string

Ken Aoshima

http://www.w3.org/2001/XMLSchema#string

Kenichi Nomoto

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Okamoto

http://www.w3.org/2001/XMLSchema#string

Mai Uesugi

http://www.w3.org/2001/XMLSchema#string

Makoto Asano

http://www.w3.org/2001/XMLSchema#string

Osamu Tohyama

http://www.w3.org/2001/XMLSchema#string

Paul J McCracken

http://www.w3.org/2001/XMLSchema#string

Satoshi Kawano

http://www.w3.org/2001/XMLSchema#string

P2860

Microtubule-binding agents: a dynamic field of cancer therapeutics.

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

Microtubules as a target for anticancer drugs

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

Hypoxia-inducible expression of tumor-associated carbonic anhydrases

Molecular mechanisms and clinical applications of angiogenesis

Mechanisms of angiogenesis

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

P304

1334-1342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12488

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264199872

http://www.w3.org/2001/XMLSchema#string

P698

25060424

http://www.w3.org/2001/XMLSchema#string

P932

4462349

http://www.w3.org/2001/XMLSchema#string